.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Express Scripts
Harvard Business School
Julphar
Argus Health
Teva
McKinsey
US Department of Justice
Dow
Queensland Health

Generated: July 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203546

« Back to Dashboard
NDA 203546 describes POTASSIUM CITRATE, which is a drug marketed by Impax Labs Inc, Zydus Pharms Usa Inc, and Ut Sw Medctr, and is included in three NDAs. It is available from four suppliers. Additional details are available on the POTASSIUM CITRATE profile page.

The generic ingredient in POTASSIUM CITRATE is potassium citrate. There are two hundred and twenty-eight drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the potassium citrate profile page.

Summary for NDA: 203546

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Therapeutic Nutrients/Minerals/Electrolytes
Formulation / Manufacturing:see details

Pharmacology for NDA: 203546

Suppliers and Packaging for NDA: 203546

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
POTASSIUM CITRATE
potassium citrate
TABLET, EXTENDED RELEASE;ORAL 203546 ANDA Cadila Healthcare Limited 65841-536 65841-536-01 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (65841-536-01)
POTASSIUM CITRATE
potassium citrate
TABLET, EXTENDED RELEASE;ORAL 203546 ANDA Cadila Healthcare Limited 65841-536 65841-536-05 500 TABLET, EXTENDED RELEASE in 1 BOTTLE (65841-536-05)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength5MEQ
Approval Date:Aug 6, 2014TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength10MEQ
Approval Date:Aug 6, 2014TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength15MEQ
Approval Date:Aug 6, 2014TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Argus Health
Farmers Insurance
Deloitte
Daiichi Sankyo
Express Scripts
Boehringer Ingelheim
Cipla
Harvard Business School
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot